Pabal

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group headquartered in Saint-Prex, Switzerland, with a strong global presence in reproductive medicine and maternal health. The company is widely recognized for its leadership in developing treatments for infertility and obstetrics, including the long-acting oxytocin analogue Pabal (carbetocin) used to prevent postpartum hemorrhage. Beyond its core focus on maternal health, Ferring has expanded into gastroenterology, urology, and endocrinology, recently achieving milestones with the launch of the first FDA-approved microbiome-based therapy, Rebyota, and the gene therapy Adstiladrin for bladder cancer. Founded in 1950, the privately-held company operates in over 50 countries and maintains a robust R&D pipeline focused on innovative peptide-based medicines and advanced therapeutic modalities.